Gilead Sciences Inc.

GILD-Q

NASDAQ:GILD

59.96
0.83 (1.37%)
Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes drugs.
More at Wikipedia

Analysis and Opinions about GILD-Q

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
August 1, 2017

(A Top Pick Sept 6/16. Down 0.4%.) This was in a downtrend, but has finally broken into an uptrend. A cheap, cheap stock, trading at a single digit PE. The #1 provider of HIV drugs globally, and the #1 provider of hepatitis drugs. About 2-3 years ago, they introduced a revolutionary Hepatitis C drug which cured, so the inflow of patients dropped off. Pays about a 3% dividend. Cheap, cheap stock.

Show full opinionHide full opinion

(A Top Pick Sept 6/16. Down 0.4%.) This was in a downtrend, but has finally broken into an uptrend. A cheap, cheap stock, trading at a single digit PE. The #1 provider of HIV drugs globally, and the #1 provider of hepatitis drugs. About 2-3 years ago, they introduced a revolutionary Hepatitis C drug which cured, so the inflow of patients dropped off. Pays about a 3% dividend. Cheap, cheap stock.

COMMENT
COMMENT
July 21, 2017

This had an enormous set back from its peak, and has got to a level that is quite attractive. Has loads and loads of upside potential. Feels the downside risk is now behind it and he likes it here. It could go a fair distance.

Show full opinionHide full opinion

This had an enormous set back from its peak, and has got to a level that is quite attractive. Has loads and loads of upside potential. Feels the downside risk is now behind it and he likes it here. It could go a fair distance.

PAST TOP PICK
PAST TOP PICK
July 11, 2017

(A Top Pick April 14/16. Down 27.5%.) Most of the stocks he picks, when they get cheaper, he likes to buy more. Not only did he buy more in his fund, but he also bought more personally. It is currently at $68.96, and his model price is $114.31, a 65% increase.

Show full opinionHide full opinion

(A Top Pick April 14/16. Down 27.5%.) Most of the stocks he picks, when they get cheaper, he likes to buy more. Not only did he buy more in his fund, but he also bought more personally. It is currently at $68.96, and his model price is $114.31, a 65% increase.

SELL
SELL
June 29, 2017

Growth rate has been completely decimated based on its business model. The stock really came down, but bounced up in the last couple of weeks with the rest of the biotech space. It is now stuck at around the 200-day moving average. Their growth rate has come down to the low single digits, and is still trading at a pretty decent multiple, 9X earnings. If you own, consider Selling and look at something like Celgene (CELG-Q).

Show full opinionHide full opinion

Growth rate has been completely decimated based on its business model. The stock really came down, but bounced up in the last couple of weeks with the rest of the biotech space. It is now stuck at around the 200-day moving average. Their growth rate has come down to the low single digits, and is still trading at a pretty decent multiple, 9X earnings. If you own, consider Selling and look at something like Celgene (CELG-Q).

HOLD
HOLD
June 22, 2017

A very important story. They had a Hep C drug that was so good it was curing everybody, so it is running out. Everybody underestimated how fast it was happening. This is trading at about 8X earnings. Has a great dividend yield and lots of cash and an incredible balance sheet. They have an HIV drug which is very strong and does well. Feels they have to do something with their cash and move in a different direction by making an acquisition. At this point, the stock is really giving the company zero value for their Hep C business. There is some good value in their pipeline. You aren’t paying a lot for the company right now with their free cash flow yield of almost 9%.

Show full opinionHide full opinion

A very important story. They had a Hep C drug that was so good it was curing everybody, so it is running out. Everybody underestimated how fast it was happening. This is trading at about 8X earnings. Has a great dividend yield and lots of cash and an incredible balance sheet. They have an HIV drug which is very strong and does well. Feels they have to do something with their cash and move in a different direction by making an acquisition. At this point, the stock is really giving the company zero value for their Hep C business. There is some good value in their pipeline. You aren’t paying a lot for the company right now with their free cash flow yield of almost 9%.

COMMENT
COMMENT
June 21, 2017

(Market Call Minute.) Pretty much a one product company treating hepatitis C. Sales are falling and the price is being challenged. The good news is that they have a huge cache of cash, 30%.

Show full opinionHide full opinion

(Market Call Minute.) Pretty much a one product company treating hepatitis C. Sales are falling and the price is being challenged. The good news is that they have a huge cache of cash, 30%.

DON'T BUY
DON'T BUY
June 15, 2017

This is a volatile stock, which means the option premiums are pretty expensive on it. If you are bullish on this, he wouldn’t Buy an option, but would be more inclined to write a Put. Not sure he would buy an option on this.

Show full opinionHide full opinion

This is a volatile stock, which means the option premiums are pretty expensive on it. If you are bullish on this, he wouldn’t Buy an option, but would be more inclined to write a Put. Not sure he would buy an option on this.

PAST TOP PICK
PAST TOP PICK
June 7, 2017

(A Top Pick March 17/16. Down 26%.) This has been a tough name. He sold his holdings in February. Their hep C and HIV drugs have been under a lot of pressure from competition and lower drug prices.

Show full opinionHide full opinion

(A Top Pick March 17/16. Down 26%.) This has been a tough name. He sold his holdings in February. Their hep C and HIV drugs have been under a lot of pressure from competition and lower drug prices.

PAST TOP PICK
PAST TOP PICK
June 2, 2017

(A Top Pick March 9/16. Down 24%.) He still loves this one.

Show full opinionHide full opinion

(A Top Pick March 9/16. Down 24%.) He still loves this one.

TOP PICK
TOP PICK
June 2, 2017

Has been waiting for the stock to get down to a target price, which it has now reached. Closed at $64.62. His model price is $111.83, a 73% upside. Dividend yield of 3.2%. (Analysts’ price target is $76.50.)

Show full opinionHide full opinion

Has been waiting for the stock to get down to a target price, which it has now reached. Closed at $64.62. His model price is $111.83, a 73% upside. Dividend yield of 3.2%. (Analysts’ price target is $76.50.)

HOLD
HOLD
May 18, 2017

His opinion on this is quite good. It has been under pressure for a number of reasons. A lot of these companies have been under pressure for pricing. There has been some speculation that some of their drugs have a lot of competition. They have an HIV drug. This looks so cheap at this time. He shows a 33% Return on Invested Capital. They used to have a 60%, but a 33% is still very good. The valuation is almost too good to be true.

Show full opinionHide full opinion

His opinion on this is quite good. It has been under pressure for a number of reasons. A lot of these companies have been under pressure for pricing. There has been some speculation that some of their drugs have a lot of competition. They have an HIV drug. This looks so cheap at this time. He shows a 33% Return on Invested Capital. They used to have a 60%, but a 33% is still very good. The valuation is almost too good to be true.

COMMENT
COMMENT
May 17, 2017

This is under pressure. Technically, you have declining fundamental trends. It is trading at a reduced valuation compared to historical comps.

Show full opinionHide full opinion

This is under pressure. Technically, you have declining fundamental trends. It is trading at a reduced valuation compared to historical comps.

PAST TOP PICK
PAST TOP PICK
May 15, 2017

(A Top Pick April 21/16. Down 33.5%.) World’s largest provider of HIV medication. In the last 3-4 years, it became the market leader in providing hepatitis C medication, which actually cures the patient. It has a 13% free cash flow yield and trades at about 8X earnings with over a 3% dividend that will increase every year for the next several years. This is worth in the $90’s.

Show full opinionHide full opinion

(A Top Pick April 21/16. Down 33.5%.) World’s largest provider of HIV medication. In the last 3-4 years, it became the market leader in providing hepatitis C medication, which actually cures the patient. It has a 13% free cash flow yield and trades at about 8X earnings with over a 3% dividend that will increase every year for the next several years. This is worth in the $90’s.

COMMENT
COMMENT
May 10, 2017

The company invented a drug that didn’t just help the patients, it cured the disease within 12 months. It would have been better business for them if they had invented a drug that merely made the disease better. A very profitable company, but he wouldn’t want to be an owner because revenues are going to be going down.

Show full opinionHide full opinion

The company invented a drug that didn’t just help the patients, it cured the disease within 12 months. It would have been better business for them if they had invented a drug that merely made the disease better. A very profitable company, but he wouldn’t want to be an owner because revenues are going to be going down.

COMMENT
COMMENT
May 10, 2017

This has been one of his worst performers. His cost base is around $80. Trading at 8X this year’s earnings. He is going to give this one more quarter. We need to see their pipeline start to fill out and we need to see M&A coming to progression.

Show full opinionHide full opinion

This has been one of his worst performers. His cost base is around $80. Trading at 8X this year’s earnings. He is going to give this one more quarter. We need to see their pipeline start to fill out and we need to see M&A coming to progression.

Showing 61 to 75 of 241 entries